# US 2026/0217789 A1 · Glycoengineered polypeptides targeting anti-podocyte autoantibodies and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0217789 A1
- Document ID: US20260217789A1
- Status: Published application
- Kind: A1
- Application number: 19/144,979
- Filed: 2024-01-05
- Published: 2026-07-30
- Earliest claimed: 2023-01-05
- Assignees: GlycoEra AG
- Applicants: GlycoEra AG
- Inventors: Ganesh Venkataraman Kaundinya; Tanmoy Chinmoy Ganguly; Rainer Follador; Manuela Mally; Jonathan Albert Back; Michela Manni
- Web page: https://patentgrep.com/patent/US20260217789A1

## CPC

- C07K 14/7056: {Lectin superfamily, e.g. CD23, CD72}
- A61K 38/178: {Lectin superfamily, e.g. selectins}
- A61P 13/12: of the kidneys
- C07K 16/2851: {against the lectin superfamily, e.g. CD23, CD72}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 16/06: from serum
- C07K 2317/21: from primates, e.g. man
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided herein are glycoengineered polypeptides comprising a first moiety comprising one or more peptides that specifically binds to an anti-podocyte autoantibody and a second moiety comprising one or more glycans conjugated to the first moiety at one or more glycosylation sites. Also provided herein are nucleic acid sequence encoding provided glycoengineered polypeptides. Further provided herein are compositions comprising glycoengineered polypeptides and/or nucleic acids encoding the same, as well as methods of making and using the same.

## Claims

### Claim 1

A glycoengineered polypeptide comprising:
(a) a first moiety comprising one or more peptides that specifically binds to an anti-podocyte autoantibody or a fragment or a complex thereof; and
(b) a second moiety comprising one or more glycans conjugated to the first moiety at one or more glycosylation sites, wherein the anti-podocyte autoantibody is:
(i) an anti-PLA2R autoantibody or a fragment or a complex thereof;
(ii) an anti-THSD7A autoantibody or a fragment or a complex thereof;
(iii) an anti-NELL1 autoantibody or a fragment or a complex thereof;
(iv) an anti-NEP autoantibody or a fragment or a complex thereof;
(v) an anti-EXT1 autoantibody or a fragment or a complex thereof; or
(vi) an anti-EXT2 autoantibody or a fragment or a complex thereof.

### Claim 2 (depends on 1)

The glycoengineered polypeptide of claim 1, wherein the glycoengineered polypeptide is capable of binding to any one, or all, or a combination of:
an anti-PLA2R autoantibody or a fragment or a complex thereof;
an anti-THSD7A autoantibody or a fragment or a complex thereof;
an anti-NELL autoantibody or a fragment or a complex thereof;
an anti-NEP autoantibody or a fragment or a complex thereof;
an anti-EXT1 autoantibody or a fragment or a complex thereof; and
an anti-EXT2 autoantibody or a fragment or a complex thereof.

### Claim 3 (depends on 1, 2)

The glycoengineered polypeptide of claim 1 or 2, wherein the second moiety specifically binds to one or more endocytic receptors chosen from: an asialoglycoprotein receptor (ASGPR); a mannose binding receptor, a Cluster of Differentiation 206 (CD206) receptor; a DC-SIGN (Cluster of Differentiation 209 or CD209) receptor; a C-Type Lectin Domain Family 4 Member G (LSECTin) receptor; a macrophage inducible Ca2+-dependent lectin receptor (Mincle); a L-SIGN CD209L receptor; dectin-1; dectin-2, langerin, macrophage mannose 2 receptor, BDCA-2, DCIR, MBL, MDL, MICL, CLEC2, CLEC10, DNGR1, CLEC12B, DEC-205, and mannose 6 phosphate receptor (M6PR), or a combination thereof.

### Claim 4

The glycoengineered polypeptide of any one of the preceding claims, wherein the glycan comprises a terminal GlcNac, a terminal GalNac, or a terminal Gal.

### Claim 5

The glycoengineered polypeptide of any one of the preceding claims, wherein the one or more glycans is an N-glycan, optionally wherein the N-glycan is linked to the first moiety of the glycoengineered polypeptide at 1, 2, 3, 4 or 5 N-glycosylation sites.

### Claim 6

The glycoengineered polypeptide of any one of the preceding claims, wherein the one or more glycans comprise a glycan structure comprising GlcNAc2-Man3-GlcNAc2, GalNAc2-GlcNAc2-Man3-GlcNAc2, Gal2-GlcNAc2-Man3-GlcNAc2, GlcNAc1-Man3-GlcNAc2, Gal2-GlcNAc2-Man3-GlcNAc2, Gal1-GlcNAc2-Man3-GlcNAc2, GalNAc1-GlcNAc2-Man3-GlcNAc2, GlcNAc3-Man3-GlcNAc2, GlcNAc4-Man3-GlcNAc2, Gal3-GlcNAc3-Man3-GlcNAc2, GalNAc3-GlcNAc3-Man3-GlcNAc2, GalNAc4-GlcNAc4-Man3-GlcNAc2, Gal4-GlcNAc4-Man3-GlcNAc2, or Man-6-P-N-glycan.

### Claim 7 (depends on 6)

The glycoengineered polypeptide of claim 6, wherein the glycan structure comprises a monoantennary structure, biantennary structure, a triantennary structure, or a tetraantennary structure.

### Claim 8 (depends on 6, 7)

The glycoengineered polypeptide of claim 6 or 7, wherein the glycan structure comprises a biantennary structure optionally, wherein the glycan structure comprises a biantennary GalNAc.

### Claim 9 (depends on 8)

The glycoengineered polypeptide of claim 8, wherein the biantennary GalNac binds to an asialoglycoprotein receptor (ASGPR) or a fragment or variant thereof, or a complex comprising ASGPR.

### Claim 10 (depends on 5, 6, 7, 8, 9)

The glycoengineered polypeptide of any one of claims 5-9, wherein the N-glycan has a structure of:
wherein the black square represents an N-acetyl galactosamine (GalNAc), the white square represents an N-acetylglucosamine (GlcNAc) residue and the black circle represents a mannose (Man) residue, and wherein X represents an amino acid residue of the first moiety.

### Claim 11 (depends on 5, 6, 7, 8, 9, 10)

The glycoengineered polypeptide of any one of claims 5-10, wherein the N-glycan is conjugated to the first moiety of the glycoengineered polypeptide at at least one, two, three, or four N-glycosylation sites.

### Claim 12 (depends on 5, 6, 7, 8, 9, 10, 11)

The glycoengineered polypeptide of any one of claims 5-11, wherein the N-glycosylation site comprises a consensus sequence of N-X-S/T or N-X-C, wherein X is any amino acid except proline.

### Claim 13 (depends on 5, 6, 7, 8, 9, 10, 11, 12)

The glycoengineered polypeptide of any one of claims 5-12, wherein the N-glycosylation site is naturally occurring.

### Claim 14 (depends on 5, 6, 7, 8, 9, 10, 11, 12)

The glycoengineered polypeptide any one of claims 5-12, wherein the N-glycosylation site is engineered into the amino acid sequence of the first moiety.

### Claim 15 (depends on 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The glycoengineered polypeptide of any one of claims 3-14, wherein the endocytic receptor is or comprises ASGPR or a fragment or variant thereof, or a complex comprising ASGPR, optionally, wherein when the endocytic receptor is ASGPR, the glycan structure of the second moiety comprises a terminal GalNac.

### Claim 16

The glycoengineered polypeptide of any one of the preceding claims, wherein the first moiety comprises one or more peptides that specifically bind to an anti-PLA2R autoantibody or a fragment thereof.

### Claim 17 (depends on 16)

The glycoengineered polypeptide of claim 16, wherein the one or more peptides that specifically bind to an anti-PLA2R autoantibody are each conjugated to a second moiety.

### Claim 18 (depends on 16, 17)

The glycoengineered polypeptide of claim 16 or 17, wherein the one or more peptides that specifically bind to an anti-PLA2R autoantibody is a soluble peptide.

### Claim 19 (depends on 16, 17, 18)

The glycoengineered polypeptide of any one of claims 16-18, wherein the one or more peptides that specifically bind to an anti-PLA2R autoantibody comprises an epitope that is recognized by an anti-PLA2R autoantibody.

### Claim 20 (depends on 16, 17, 18, 19)

The glycoengineered polypeptide of any one of claims 16-19, wherein the one or more peptides that specifically bind to an anti-PLA2R autoantibody comprises a PLA2R polypeptide, or a fragment or a variant thereof.

### Claim 21 (depends on 20)

The glycoengineered polypeptide of claim 20, wherein the PLA2R polypeptide is provided as SEQ ID NO: 1 (e.g., with or without the signal peptide), SEQ ID NO: 38 (e.g., with or without the signal peptide), or SEQ ID NO: 39.

### Claim 22 (depends on 20, 21)

The glycoengineered polypeptide of claim 20 or 21, wherein the one or more peptides comprise at least 5% of a full length PLA2R polypeptide, or a PLA2R polypeptide sequence provided in SEQ ID NO: 1 (e.g., with or without the signal peptide), SEQ ID NO: 38 (e.g., with or without the signal peptide), or SEQ ID NO: 39.

### Claim 23 (depends on 20, 21, 22)

The glycoengineered polypeptide of any one of claims 20-22, wherein the one or more peptides comprise one or more domains of a PLA2R polypeptide, or fragments or variants thereof.

### Claim 24 (depends on 23)

The glycoengineered polypeptide of claim 23, wherein the one or more domains of a PLA2R polypeptide include: an N-terminal cysteine rich (CysR) domain, a fibronectin 2 domain, and eight C-type lectin-like domains (CTLD), e.g., CTLD1, CTLD2, CTLD3, CTLD4, CTLD5, CTLD6, CTLD7 or CTLD8.

### Claim 25 (depends on 23, 24)

The glycoengineered polypeptide of claim 23 or 24, wherein the one or more peptides comprise:
(i) an N-terminal cysteine rich (CysR) domain, or a fragment or variant thereof;
(ii) a fibronectin 2 domain, or a fragment or variant thereof;
(iii) a CTLD1 domain, or a fragment or variant thereof;
(iv) a CTLD2 domain, or a fragment or variant thereof;
(v) a CTLD3 domain, or a fragment or variant thereof;
(vi) a CTLD4 domain, or a fragment or variant thereof;
(vii) a CTLD5 domain, or a fragment or variant thereof;
(viii) a CTLD6 domain, or a fragment or variant thereof;
(ix) a CTLD7 domain, or a fragment or variant thereof;
(x) a CTLD8 domain, or a fragment or variant thereof; or
(xi) any combination of (i)-(x).

### Claim 26 (depends on 25)

The glycoengineered polypeptide of claim 25, wherein the one or more peptides comprise: an N-terminal cysteine rich (CysR) domain, or a fragment or variant thereof; an N-terminal cysteine rich (CysR) domain, or a fragment or variant thereof; a CTLD1 domain, or a fragment or variant thereof; and a CTLD2 domain, or a fragment or variant thereof.

### Claim 27 (depends on 20, 21, 22, 23, 24, 25, 26)

The glycoengineered polypeptide of any one of claims 20-26, wherein the one or more peptides comprise a sequence having at least 85% identity to a PLA2R polypeptide sequence provided in:
(i) SEQ ID NO: 1 with or without the signal peptide of SEQ ID NO: 14,
(ii) SEQ ID NO: 38 with or without the signal peptide of SEQ ID NO: 14, or
(iii) SEQ ID NO: 39.

### Claim 28 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27)

The glycoengineered polypeptide of any one of claims 16-27, wherein the one or more peptides comprises one or more additional amino acid residues on the 5′ and/or 3′ end of the sequence.

### Claim 29 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28)

The glycoengineered polypeptide of any one of claims 16-28, wherein the one or more peptides that specifically bind to an anti-PLA2R autoantibody comprises a contiguous chain of amino acids comprising at least 5% of the amino acid of SEQ ID NO: 1 (e.g., with or without the signal peptide), SEQ ID NO: 38 (e.g., with or without the signal peptide), or SEQ ID NO: 39.

### Claim 30 (depends on 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29)

The glycoengineered polypeptide of any one of claims 16-29, wherein the one or more peptides that specifically bind to an anti-PLA2R autoantibody comprises an antibody agent comprising an antigen binding fragment.

### Claim 31 (depends on 30)

The glycoengineered polypeptide of claim 30, wherein the antibody agent comprises a full antibody, a Fab fragment, an scFv, a nanobody, a duobody, or a single domain antibody (e.g., a VHH).

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The glycoengineered polypeptide of any one of claims 1-15, wherein the first moiety comprises one or more peptides that specifically bind to an anti-NELL autoantibody or a fragment thereof.

### Claim 33 (depends on 32)

The glycoengineered polypeptide of claim 32, wherein the one or more peptides that specifically bind to an anti-NELL autoantibody are each conjugated to a second moiety.

### Claim 34 (depends on 32, 33)

The glycoengineered polypeptide of claim 32 or 33, wherein the one or more peptides that specifically bind to an anti-NELL autoantibody is a soluble polypeptide.

### Claim 35 (depends on 32, 33, 34)

The glycoengineered polypeptide of any one of claims 32-34, wherein the one or more peptides that specifically bind to an anti-NELL autoantibody comprises an epitope that is recognized by an anti-NELL autoantibody.

### Claim 36 (depends on 32, 33, 34, 35)

The glycoengineered polypeptide of any one of claims 32-35, wherein the one or more peptides that specifically bind to an anti-NELL autoantibody comprises a NELL polypeptide, or a fragment or a variant thereof, optionally wherein the NELL polypeptide is provided as SEQ ID NO: 9.

### Claim 37 (depends on 36)

The glycoengineered polypeptide of claim 36, wherein the fragment comprises at least 5% of a full length NELL polypeptide.

### Claim 38 (depends on 32, 33, 34, 35, 36, 37)

The glycoengineered polypeptide of any one of claims 32-37, wherein the one or more peptides comprises a sequence having at least 85% identity to the amino acid sequence of SEQ ID NO: 9.

### Claim 39 (depends on 32, 33, 34, 35, 36, 37, 38)

The glycoengineered polypeptide of any one of claims 32-38, wherein the one or more peptides that specifically bind to an anti-NELL autoantibody comprises an antibody agent comprising an antigen binding fragment.

### Claim 40 (depends on 39)

The glycoengineered polypeptide of claim 39, wherein the antibody agent comprises a full antibody, a Fab fragment, an scFv, a nanobody, a duobody or a single domain antibody (e.g., a VHH).

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15)

The glycoengineered polypeptide of any one of claims 1-15, wherein the first moiety comprises one or more peptides that specifically bind to an anti-THSD7A autoantibody or a fragment thereof.

### Claim 42 (depends on 41)

The glycoengineered polypeptide of claim 41, wherein the one or more peptides that specifically bind to an anti-THSD7A autoantibody are each conjugated to a second moiety.

### Claim 43 (depends on 41, 42)

The glycoengineered polypeptide of claim 41 or 42, wherein the one or more peptides that specifically bind to an anti-THSD7A autoantibody is a soluble polypeptide.

### Claim 44 (depends on 41, 42, 43)

The glycoengineered polypeptide of any one of claims 41-43, wherein the one or more peptides that specifically bind to an anti-THSD7A autoantibody comprises an epitope that is recognized by an anti-THSD7A autoantibody.

### Claim 45 (depends on 41, 42, 43, 44)

The glycoengineered polypeptide of any one of claims 41-44, wherein the one or more peptides that specifically bind to an anti-THSD7A autoantibody comprises a THSD7A polypeptide, or a fragment or a variant thereof optionally, wherein the THSD7A polypeptide is provided as SEQ ID NO: 10.

### Claim 46 (depends on 45)

The glycoengineered polypeptide of claim 45, wherein the one or more peptides that specifically bind to an anti-THSD7A autoantibody comprises a fragment of a THSD7A polypeptide, optionally wherein the fragment comprises at least 5% of a full length THSD7A polypeptide.

### Claim 47 (depends on 41, 42, 43, 44, 45, 46)

The glycoengineered polypeptide of any one of claims 41-46, wherein the one or more peptides comprise one or more domains of a THSD7A polypeptide.

### Claim 48 (depends on 41, 42, 43, 44, 45, 46, 47)

The glycoengineered polypeptide of any one of claims 41-47, wherein the one or more peptides comprises a sequence having at least 85% identity to SEQ ID NO: 10.

### Claim 49 (depends on 41, 42, 43, 44, 45, 46, 47, 48)

The glycoengineered polypeptide of any one of claims 41-48, wherein the one or more peptides that specifically bind to an anti-THSD7A autoantibody comprises an antibody agent comprising an antigen binding fragment.

### Claim 50 (depends on 49)

The glycoengineered polypeptide of claim 49, wherein the antibody agent comprises a full antibody, a Fab fragment, an scFv, a nanobody, a duobody, or a single domain antibody (e.g., a VHH).

### Claim 51

The glycoengineered polypeptide of any the preceding claims wherein the first moiety comprises:
(i) one or more anti-PLA2R autoantibody binding polypeptides;
(ii) one or more anti-THSD7A autoantibody binding polypeptides; and/or
(iii) one or more anti-NELL autoantibody binding polypeptides;

### Claim 52

The glycoengineered polypeptide of any one of the preceding claims, wherein the polypeptide comprises one or more additional elements chosen from:
(a) a linker,
(b) a spacer,
(c) a cleavage peptide, e.g., an IRES or a protease cleavage site,
(d) a signal peptide,
(e) a tag, e.g., a cleavable tag,
(f) a half-life extender domain, e.g., an Fc domain or albumin, or
(g) any combination of (a)-(f).

### Claim 53

The glycoengineered polypeptide of any one of the preceding claims, wherein the second moiety is conjugated to the first moiety in vivo.

### Claim 54 (depends on 53)

The glycoengineered polypeptide of claim 53, wherein the conjugation occurs in a cell, optionally wherein the cell is a Leishmania cell.

### Claim 55 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52)

The glycoengineered polypeptide of any one of claims 1-52, wherein the second moiety is conjugated to the first moiety by chemical conjugation, optionally wherein chemical conjugation comprises click chemistry.

### Claim 56

A polynucleotide encoding the glycoengineered polypeptide of any one of the preceding claims.

### Claim 57 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

A composition comprising a glycoengineered polypeptide of any one of claims 1-55.

### Claim 58 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

A composition comprising a population of glycoengineered polypeptides of any one of claims 1-55, wherein the population of glycoengineered polypeptides has an N-glycan profile that is at least 30% homogeneous at one or more of the N-glycosylation site(s).

### Claim 59 (depends on 10, 58)

The composition of claim 58, wherein the N-glycan profile comprises about 30% of the N-glycan of the structure provided in claim 10.

### Claim 60 (depends on 57, 58, 59)

The composition of any one of claims 57-59, wherein the composition is a pharmaceutical composition.

### Claim 61 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55)

A Leishmania host cell expressing a glycoengineered polypeptide of any one of claims 1-55, wherein the cell comprises a polynucleotide sequence encoding a glycoengineered polypeptide.

### Claim 62 (depends on 60)

A method comprising:
administering to a subject a pharmaceutical composition of claim 60.

### Claim 63 (depends on 62)

The method of claim 62, wherein the subject has or is diagnosed as having idiopathic membranous nephropathy (iMN).

### Claim 64 (depends on 62, 63)

The method of claim 62 or 63, wherein the method is a treatment method or a prevention method.

### Claim 65 (depends on 60)

A method of treating and/or preventing idiopathic membranous nephropathy (iMN) in a subject, the method comprising, administering to a subject a pharmaceutical composition of claim 60.

### Claim 66 (depends on 62, 63, 64, 65)

The method of any one of claims 62-65, wherein the glycoengineered polypeptide is capable of simultaneously binding to an anti-podocyte autoantibody with the first moiety and binding to an endocytic receptor-expressing cell with the second moiety, thereby causing the anti-podocyte autoantibody to be internalized into a cell.

### Claim 67 (depends on 66)

The method of claim 66, wherein internalization comprises transporting to a lysosome and/or degradation.

### Claim 68 (depends on 66, 67)

The method of claim 66 or 67, wherein the anti-podocyte autoantibody and the glycoengineered polypeptide are internalized.

### Claim 69 (depends on 66, 67, 68)

The method of any one of claims 66-68, wherein:
(i) the anti-podocyte autoantibody comprises: an anti-PLA2R autoantibody or a fragment or a complex thereof; an anti-THSD7A autoantibody or a fragment or a complex thereof; an anti-NELL autoantibody or a fragment or a complex thereof, or a combination thereof; and/or
(ii) the endocytic receptor is ASGPR or a variant or fragment thereof.

### Claim 70 (depends on 62, 63, 64, 65, 66, 67, 68, 69)

The method of any one of claims 62-69, wherein the subject has increased levels of an anti-podocyte autoantibody as compared to a subject who does not have iMN.

### Claim 71 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any one of claims 62-70, wherein administration of the pharmaceutical composition reduces a level of an anti-podocyte autoantibody as compared to a subject who has not been administered the pharmaceutical composition or as compared to the same subject prior to administration of the pharmaceutical composition.

### Claim 72 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any one of claims 62-71, wherein administration of the pharmaceutical composition reduces and/or prevents formation and/or accumulation of an immune complex as compared to a subject who has not been administered the pharmaceutical composition or as compared to the same subject prior to administration of the pharmaceutical composition optionally wherein the immune complex comprises one or more: IgG antibodies, the anti-podocyte autoantibody, an antigen recognized by the anti-podocyte autoantibody, complement components, or combinations thereof.

### Claim 73 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any one of claims 62-72, wherein administration of the pharmaceutical composition reduces activation of a complement pathway or component thereof as compared to a subject who has not been administered the pharmaceutical composition or as compared to the same subject prior to administration of the pharmaceutical composition, optionally wherein a complement pathway comprises: a lectin pathway, a classical pathway or an alternative pathway.

### Claim 74 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73)

The method of any one of claims 62-73, wherein administration of the pharmaceutical composition reduces and/or prevents proteinuria, decreased albumin levels and/or edema as compared to a subject who has not been administered the pharmaceutical composition or as compared to the same subject prior to administration of the pharmaceutical composition.

### Claim 75 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any one of claims 62-74, wherein administration of the pharmaceutical composition reduces and/or prevents thickening of glomerular capillary walls as compared to a subject who has not been administered the pharmaceutical composition or as compared to the same subject prior to administration of the pharmaceutical composition.

### Claim 76 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method of any one of claims 62-75, wherein administration of the pharmaceutical composition reduces and/or prevents changes in structure and/or function of podocytes as compared to a subject who has not been administered the pharmaceutical composition or as compared to the same subject prior to administration of the pharmaceutical composition, optionally wherein administration of the pharmaceutical composition prevents apoptosis in podocytes; prevents an increase in intracellular calcium in podocytes; and/or prevents a decrease in cellular motility and/or adhesion of podocytes.

### Claim 77 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The method of any one of claims 62-76, wherein administration of the pharmaceutical composition treats and/or prevents the disease.

### Claim 78 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any one of claims 62-77, wherein administration of the pharmaceutical composition alleviates one or more symptoms of the disease.

### Claim 79 (depends on 60)

A method comprising,
assessing a level of an anti-podocyte autoantibody in a sample from a subject, and
administering a pharmaceutical composition of any one of claim 60,
if the level of the anti-podocyte autoantibody is higher than a comparator.

### Claim 80 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79)

The method of any one of claims 62-79, wherein the method comprises administering the pharmaceutical composition in combination with one or more additional therapies, optionally wherein the one or more additional therapies comprises a VEGF inhibitor, an anti-BAFF antibody, an anti-CD20 antibody, an anti-CD38 antibody, an anti-CD19 antibody, a Janus kinase inhibitor, a SYK inhibitor, a Factor B complement inhibitor, or a combination thereof.

### Claim 81 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80)

The method of any one of claims 62-80, wherein the administration step comprises intravenous injection, intraperitoneal injection, subcutaneous injection, transdermal injection, or intramuscular injection.

### Claim 82 (depends on 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81)

The method of any one of claims 62-81, wherein the subject is a mammal.
